Multiple preclinical studies have shown the promotion of T cell function and anti-tumor activity with MAPK inhibition—particularly MEK inhibition—in combination with immunostimulatory therapeutics such as PD-1 or PD-L1 checkpoint inhibition [80,81,82]. Here, MAP2K7 is linked to neoplasm.